Zhimeng Biopharma
PrivateLast Round
Series B
Nov 8, 2021
Total Funding Raised
$98M
Company Overview
Zhimeng Biopharma operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series B round in November 2021.
Zhimeng Biopharma is a biopharmaceutical company that develops innovative small-molecule therapeutics for the treatment of chronic hepatitis B and neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Zhimeng Biopharma Comparables
Compare Zhimeng Biopharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NeuShen Therapeutics | 78% | |
| Shanghai Hepu Pharmaceutical Co., Ltd. | 74% | |
| Brii Biosciences | 74% |
For institutional investors. Book with your work email.
Zhimeng Biopharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 8, 2021 | ||||
| Series A | Nov 6, 2020 | ||||
| Pre Seed | Nov 11, 2019 |
For institutional investors. Book with your work email.
Zhimeng Biopharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Photon Fund | Series A |
| SDIC Unity Capital | Series A |
| 中南创投基金 | Series A |
| Shenzhen Dachen Caizhi Venture Capital Management | Series B |
| Trinity Innovation Fund | Series A |
| Advantech Capital | Series B |
| Lake Capital | Series A, Pre Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 5, 2026
Monthly visitors increased 112% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 31, 2026
As of Oct '26, Zhimeng Biopharma is developing ZM-H1505R, a capsid inhibitor for the functional cure of chronic hepatitis B, which has entered a pivotal Phase 3 trial in China.
For institutional investors. Book with your work email.
Zhimeng Biopharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Zhimeng Biopharma's valuation, stock price, and market status.
Is Zhimeng Biopharma a public or private company?
Zhimeng Biopharma is a private company.
What is the current stock price of Zhimeng Biopharma?
Zhimeng Biopharma is a private company, so its shares have no public market price. Caplight tracks Zhimeng Biopharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Zhimeng Biopharma worth (valuation)?
Valuation information for Zhimeng Biopharma is not publicly available.
Can I buy Zhimeng Biopharma stock?
Zhimeng Biopharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Zhimeng Biopharma's last funding round?
Zhimeng Biopharma's most recent funding round was Series B on November 8, 2021.
Who are the main investors in Zhimeng Biopharma?
Key investors in Zhimeng Biopharma include Shenzhen Dachen Caizhi Venture Capital Management, Trinity Innovation Fund, Advantech Capital, Lake Capital, Shenzhen Capital Group.
Will Zhimeng Biopharma IPO soon?
No public IPO plans have been announced for Zhimeng Biopharma.
How can I track Zhimeng Biopharma secondary market activity?
Caplight tracks bids, offers, and trades in Zhimeng Biopharma's shares on secondary markets.